CHMP nod for Novartis's Jakavi
This article was originally published in Scrip
The EU's CHMP has granted a positive opinion to Novartis's oral JAK inhibitor Jakavi (ruxolitinib; licensed from Incyte) for the treatment of patients with myelofibrosis.
You may also be interested in...
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.